Coronary Vasomotor Response After Riociguat Exposure (CORONARIES)

Bayer

Status and phase: Withdrawn; Phase 2

Conditions: Coronary Artery Disease

Treatments: Drug: Riociguat (BAY63-2521)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01165931

14550

Details and patient eligibility

About

The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients with coronary artery disease

Exclusion criteria

• Patents with coronary artery disease with >/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery [LAD], left circumflex coronary artery [LCX] or right coronary artery [RCA]) undergoing cardiac catheterization

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Arm 1

Experimental group

Treatment:

Drug: Riociguat (BAY63-2521)